Status:

COMPLETED

STEREO-POSTOP 01 (PostOperative Hypofractionated Stereotactic Body Radiotherapy ) - GORTEC 2017-03

Lead Sponsor:

Centre Jean Perrin

Collaborating Sponsors:

GORTEC

Conditions:

Head and Neck Neoplasms

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The main objective of this national, open-label, non-randomized phase II trial is to evaluate severe late toxicity of postoperative hypofractionated stereotactic radiotherapy (SBRT) in the treatment o...

Eligibility Criteria

Inclusion

  • Operated squamous cell carcinoma of oral cavity (lips excepted) or oropharynx
  • pT1 or pT2 ((UICC 7th edition 2009)
  • Indication of postoperative tumor site irradiation (retained in multidisciplinary tumor board) with at least one of the following criteria :
  • positive R1 margin (re-resection not proposed)
  • close margin \< 5 mm (re-resection not proposed)
  • Margin estimated at risk, with uncertain pathological margin (re-resection not proposed)
  • N0 after surgical management of the neck (neck dissection or sentinel lymph node biopsy) or pN1 without extracapsular extension (carcinological neck dissection)
  • Age ≥ 18 years
  • ECOG status ≤ 2
  • Written signed informed consent before any specific procedure of the protocol
  • Affiliation to a social security scheme or beneficiary of such a scheme

Exclusion

  • Other histology than squamous cell carcinoma
  • pT3 or pT4
  • pT2\>3cm and R1 with concurrent chemoradiotherapy decided in multidisciplinary tumor board
  • Lymphovascular invasion justifying neck irradiation
  • Neck irradiation decided in multidisciplinary tumor board
  • Lack of at least one of the following elements :
  • pre-operative medical imaging (CT scan or MRI)
  • endoscopy report
  • surgery report
  • pathological report
  • Prior radiotherapy to the head and neck area
  • Distant metastasis
  • Pregnant or nursing (lactating) woman
  • women or men of childbearing age not taking adequate contraceptive measure
  • participation in another investigational study within 4 weeks prior to inclusion
  • History of other malignancy within 5 years prior enrollment except for basal cell carcinoma of the skin or carcinoma in situ of the cervix
  • Persons deprived of their liberty, under guardianship or curatorship, or unable to follow the trial for geographical, social or psychological reasons

Key Trial Info

Start Date :

January 23 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 28 2023

Estimated Enrollment :

90 Patients enrolled

Trial Details

Trial ID

NCT03401840

Start Date

January 23 2018

End Date

September 28 2023

Last Update

February 13 2025

Active Locations (24)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (24 locations)

1

Institut Sainte Catherine

Avignon, France

2

Institut Bergonié

Bordeaux, France

3

Polyclinique bordeaux Nord Aquitaine

Bordeaux, France

4

Centre Jean Perrin

Clermont-Ferrand, France